Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, have entered into a multi-project collaboration and licensing deal with Germany’s Merck to discover and develop new anticancer therapies. More: Merck, CR UK, ICR collaborate on cancer
read moreGlaxoSmithKline already partners with Vectura on respiratory therapies, but some say the British pharma giant could be looking to take the pair’s relationship one step further. More: GlaxoSmithKline eyes .7B bid for respiratory partner Vectura: report Source: fierce
read moreCelltrion Chairman Seo Jeong-jin has confirmed that the South Korean drugmaker has decided to build its third plant outside of South Korea and expects to start construction by year-end. More: Celltrion's Seo says company will build next plant outside of
read moreSkittish investors grew increasingly concerned last year that Merck & Co. couldn’t replicate its Keytruda-chemo combo success in a phase 3 trial of previously untreated patients. But on Tuesday, the pharma giant silenced its doubters. More: Merck extends all-important lung-cancer
read moreGood news for pharma’s pricing power: The pitched battle over sticker prices is mostly confined to a few therapeutic areas, and drugmakers are finding safer havens in oncology and rare diseases, a new analysis shows. More: How to sidestep pricing
read moreHere are some other pharma industry stories we’re following today. More: News of Note—Thermo Fisher and Flexion; Indian inspections of U.S. facilities Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals